Justine Ra is a healthcare reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing coverage on neurology and neurodegenerative diseases. Justine holds a degree in English from The University of Michigan, Ann Arbor.
ALX-001 is currently being studied in a Phase Ib safety study and designs for a Phase II ALX-001 proof-of-concept study are underway.
The AD and PD drug aims to reduce the level of neurotoxic proteins, thereby improving information flow across the axonal transport.
The three-year data for Sotyktu indicates a consistent safety profile and strong efficacy.